Episode 104 – Insights from the Global Urticaria Forum (GUF)

CSU expert Professor Ana Maria Giménez-Arnau joins Professor Torsten Zuberbier to discuss the past, present, and future of treatment for CSU, exploring the current treatment paradigm and new approaches on the horizon that might bring us closer to disease-modifying therapies.Disclosure statement: AGA is or recently was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen, AstraZeneca, Avene, Blue -Print,  Celldex, Escient Pharmaceuticals, Genentech, GSK, Harmonic Bio, Instituto Carlos III- FEDER, Jaspers, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Noucor,  Novartis, Sanofi–Regeneron , Septerna, Servier, Thermo Fisher Scientific, Uriach Pharma.Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form ATU: https://forms.office.com/e/m6a2uEdsUH